ArticleACS medicinal chemistry letters2023
Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae.
Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Physiological Mechanisms in Pregnancy and Their Relevance to the Clinical Management of Perinatal Mental Illness.Journal of clinical medicine · 2026Review
- A systematic safety assessment of zuranolone: real-world adverse event analysis from the FAERS database.Archives of women's mental health · 2026Article
- GABADrug design, development and therapy · 2026Review
- Epidemiology, pathophysiology, and interventions for postpartum depression: Systematic review.World journal of clinical cases · 2025Article
- Activation of zona incerta gamma-aminobutyric acid-ergic neurons alleviates depression-like and anxiety-like behaviors induced by chronic restraint stress.World journal of psychiatry · 2025Article
- Postpartum depression-associated localized neural dysfunction: a voxel-wise meta-analysis of amplitude and synchronization alterations in resting-state fMRI.Frontiers in psychiatry · 2025Review
- Advancing depression treatment: the role of sigma receptor ligands.Frontiers in neuroscience · 2025Review
- Protection from oxygen-glucose deprivation by neurosteroid treatment in primary neurons and oligodendrocytes.In vitro cellular & developmental biology. Animal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postpartum depression (PPD) affects 10-15% of new mothers globally. Marking a pivotal shift in treatment, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone) as the first oral medication for PPD in adults. This major depressive episode can emerge after childbirth or in pregnancy's later stages. Previously, PPD treatments were restricted to IV injections administered in select healthcare facilities. Childbirth instigates hormonal, physiological, and emotional shifts, with a stark drop in mood-regulating hormones like estrogen and progesterone possibly triggering depression. The role of serotonin in PPD is undeniable. Psychosocial stressors, such as neonatal care burdens and societal pressures, further amplify the risk. This Patent Highlight underscores the introduction of zuranolone as a beacon of hope for an effective and accessible treatment, which may benefit many postnatal women worldwide.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.